ADVANCED DRUG DELIVERY REVIEWS先进药物递送评论
ADVANCED DRUG DELIVERY REVIEWS(英文缩写 ADV DRUG DELIVER REV),ISSN 0169-409X,eISSN 1872-8294,中文译名:先进药物递送评论 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 17.873 | Q1 |
| 2022 | 16.100 | Q1 |
| 2023 | 15.200 | Q1 |
| 2024 | 17.600 | Q1 |
| 2025 | 21.000 | Q1 |
ADVANCED DRUG DELIVERY REVIEWS 最新收录文献
-
1. Poly(2-oxazoline)s and poly(2-oxazine)s: An overview of stealth properties, pharmacokinetics, and immunogenicity.
PMID:日期:2026-10-01For over four decades, poly(ethylene glycol) (PEG) has been the undisputed gold standard for conferring stealth properties to nanomedicines and polymer therapeutics. However, the widespread presence of pre-existing anti-PEG antibodies in the general population, which was intensified by recent mRNA COVID-19 vaccination campaigns, has exposed critical immunological liabilities, including accelerated blood clearance, hypersensitivity reactions and reduced therapeutic efficacy. Poly(2-oxazoline)s, particularly poly(2-methyl-2-oxazoline) (PMeOx) and poly(2-ethyl-2-oxazoline) (PEtOx), have emerged as promising PEG alternatives. Their hydrolytically stable amide backbone, absence of ether oxygens (key recognition motifs for anti-PEG antibodies), tunable hydrophilicity, chemical versatility, tailor-made properties and excellent antifouling characteristics position them as ideal stealth candidates. This review discusses the progress that has been made on poly(2-oxazoline)s as alternative to PEG by discussing the state-of-the-art in poly(2-oxazoline) stealth/antifouling properties, pharmacokinetics, and immunogenicity, structured by polymer type, namely PMeOx, PEtOx, and other polymers, such as chiral poly(2-oxazoline)s and poly(2-oxazine)s. This review aims to give an overview of the current status, which can be used as starting point for getting acquainted with poly(2-oxazoline)s as PEG-alternatives for those new to the field and as source of inspiration for future research in the area.
-
2. Nanozyme-mediated redox and immune homeostasis in osteoarthritis and rheumatoid arthritis.
PMID:日期:2026-09-26Osteoarthritis (OA) and rheumatoid arthritis (RA) are inflammatory joint disorders that involve overlapping immune-cell populations with distinct etiologies. Key pathological features in the microenvironments of both OA and RA are redox imbalance, and dysregulated immune responses. From the perspective of pathological microenvironment, a high level of reactive oxygen species (ROS) triggers inflammatory cascades, shifting macrophage polarization to M1 (pro-inflammatory) phenotype, leading to cartilage erosion and tissue damage. Current therapeutics comprising anti-inflammatory drug and antioxidant agents provide symptomatic relief, yet possess significant challenges especially addressing interconnected axis (redox-immune axis). Nanozymes, catalytic nanomedicine with their enzyme-mimicking properties such as peroxidase (POD), superoxide dismutase (SOD), and catalase (CAT), alongside with high stability, adjustable catalytic activities and adaptability to specific microenvironment, have emerged as promising platform in arthritis treatment to restore redox homeostasis and immune responses. Moreover, microenvironment-adaptive and combinational nanozymes systems further advance the targeted and multimodal therapeutic strategies in arthritis. This review highlights the pathological rationale for nanozymes in OA and RA, and explores nanozymes-immune crosstalk focusing on the redox homeostasis, immune regulation, and microenvironment-sensitive or combinational platforms. Furthermore, safety concerns regarding nanozymes treatment, and future avenue of the research are drawn to advance the nanozyme-based therapies on arthritis.
-
3. Fibrosis: Bridging fundamental mechanisms to precision medicine via advanced therapeutics.
3. 纤维化：通过先进疗法将基本机制与精准医学联系起来PMID:日期:2026-09-17Fibrosis is a progressive, pan-organ pathology characterized by excessive deposition of extracellular matrix (ECM), tissue stiffening, and ultimately organ failure. Despite a deepened understanding of its molecular mechanisms, effective therapies remain scarce, largely because the dense scar ECM, elevated interstitial fluid pressure (IFP), and metabolic heterogeneity severely limit drug penetration and lead to off-target toxicity. This review integrates converging mechanisms of fibrosis with advances in precision delivery, laying out a roadmap for the development of next-generation antifibrotic therapeutics. We first summarize the multicellular core mechanisms of fibrosis-myofibroblasts, immune cells, and barrier cells-as well as the interconnected TGF-β, PDGF, WNT/β-catenin and metabolic circuits, which together generate a hostile, stiff microenvironment. Subsequently, we highlight how single-cell and spatial multi-omics, complex humanized models, and AI-driven network analysis are redefining target identification, patient stratification and the "design inputs" for advanced drug and gene delivery systems. Building on these insights, we critically evaluate stimuli-responsive nanocarriers leveraging ROS, pH, enzymatic activity or exogenous triggers, as well as local depots, microneedles and inhalation formulations capable of overcoming systemic delivery limitations and fibrotic microenvironmental barriers. Key carrier platforms-including lipid, polymeric and inorganic nanoparticles, extracellular vesicles (EVs) and protein/peptide vectors-are compared in terms of organ tropism, penetration capacity, payload types, and translational application limitations. By explicitly mapping clinical and emerging antifibrotic agents to their primary delivery barriers, we propose a pan-fibrotic framework that integrates shared core pathways with organ-specific "zip codes" and synergistically develops intelligent payloads and vehicles to achieve precise, clinically translatable antifibrotic therapy.
-
4. Corrigendum to "Near-infrared fluorescence imaging-guided targeted drug delivery in gastric tumors: From molecular design to clinical translation" [Adv. Drug Deliv. Rev. 235 (2026) 115891].
4. 对“近红外荧光成像引导胃肿瘤靶向药物递送：从分子设计到临床翻译”的更正[Adv.drug Deliv.Rev.235（2026）115891]PMID:日期:2026-09-11该文献暂无摘要。
-
5. Adipose tissue-on-Chip platforms for disease modelling, drug discovery and pharmacokinetic modelling.
5. 用于疾病建模、药物发现和药代动力学建模的脂肪组织芯片平台PMID:日期:2026-09-07Adipose tissue is increasingly recognised as a central regulator of systemic metabolism. Beyond energy storage, adipose tissue integrates nutrient sensing, endocrine signalling, and immune responses, and actively communicates with other organs to coordinate metabolic homeostasis. This functional complexity arises from the coordinated activity of adipocytes and stromal cells, whose interactions dynamically regulate both physiological and pathological states. Most in vitro experimental models used in drug development and mechanistic research have simplified this complexity, whereas in vivo models integrate systemic physiology but lack human specificity. This mismatch limits the ability to predict adipose-specific drug effects, particularly for compounds targeting metabolic pathways, inflammation, or inter-organ signalling. In pharmacological contexts this limitation is particularly relevant because adipose tissue not only acts as a therapeutic target but also influences drug distribution, bioavailability, and efficacy through lipid partitioning, endocrine signalling, and immune modulation. Models that fail to capture these features risk overlooking key mechanisms of action or mispredicting therapeutic outcomes. Microphysiological systems that reconstruct adipose tissue complexity offer a framework to bridge this gap. By integrating multiple adipose-relevant cell types, such as mature adipocytes and stromal vascular fraction cells, along with physiological perfusion and controllable microenvironments, these systems could help address how cell-cell interactions shape metabolic function and pharmacological responses. As such, they represent a translational platform to interrogate drug mechanisms, evaluate tissue-specific efficacy, and could become tools to predict systemic pharmacological effects in metabolically relevant human settings.
-
6. Molecular design and delivery of extracellular and membrane protein degradation chimeras.
6. 细胞外和膜蛋白降解嵌合体的分子设计和递送PMID:日期:2026-09-06Extracellular and membrane-associated proteins constitute a substantial therapeutic target space that remains largely inaccessible to intracellular degradation strategies based on the ubiquitin-proteasome system. Membrane and extracellular targeted protein degradation (meTPD) addresses this limitation by coupling target recognition to degradation-competent uptake and intracellular sorting rather than relying on a single receptor or platform. In this Review, we organize meTPD strategies according to their trafficking and degradation routes, including lysosome-targeting receptor-dependent systems, transmembrane E3 ligase recruitment, receptor-independent internalization, lysosomal-sorting sequences and autophagy-mediated clearance. We then examine how ligand affinity and epitope accessibility, ternary-complex geometry, linker architecture, covalency, valency, receptor recycling and degrader reuse collectively determine productive degradation. Particular attention is given to spatial selectivity across tissues, cell populations and subcellular organelles, as well as to artificial intelligence-assisted design, stimuli-responsive activation and delivery systems that regulate the exposure and trafficking of meTPDs. Finally, we discuss emerging clinical evidence, convergence with antibody-drug conjugate-derived modalities, the hook effect and plausible resistance mechanisms. By integrating molecular design, receptor biology, intracellular trafficking, delivery and pharmacodynamic considerations, this review provides a framework for selecting disease-matched degradation routes and advancing meTPDs from platform-specific demonstrations towards predictable therapeutic modalities.
-
7. Microfluidics in heart-on-a-chip platforms for cardiovascular drug discovery and cardiotoxicity assessment.
7. 用于心血管药物发现和心脏毒性评估的芯片心脏平台中的微流体PMID:日期:2026-09-05Cardiovascular disease remains the leading cause of death worldwide. The limited translational fidelity of traditional preclinical models continues to constrain the development of safer and more effective therapies. Animal studies and static two-dimensional cultures only partially reproduce human cardiac physiology, including mechanical loading, perfusion, multicellular interactions, and drug metabolism, which contribute to late-stage failure and unexpected cardiotoxicity. Accordingly, there is a growing need for human-relevant platforms that can more accurately model cardiac (patho)physiology, support drug discovery, and improve safety assessment. Microfluidic heart-on-a-chip (HoC) systems address this need by combining microfabrication, tissue engineering, and controlled fluid flow to generate miniaturized cardiac tissues with physiologically relevant biochemical, mechanical, and electrical cues. These platforms can provide real-time functional readouts, including contractility, electrophysiology, calcium handling, metabolic activity, and biomarker release, while also enabling the study of disease-relevant phenotypes such as ischemia-reperfusion injury, arrhythmias, fibrosis, and cardiomyopathy. In addition, HoC systems are increasingly being integrated with biosensors, automation, and multi-organ configurations to capture drug metabolism and inter-organ crosstalk, further improving their predictive value for efficacy and toxicity screening. In this review, we summarize the core design elements of microfluidic HoC platforms, highlight their applications in cardiovascular drug discovery and cardiotoxicity assessment, and discuss current challenges and future directions for the field.
-
8. Engineering responsive polymeric drug delivery systems via bioorthogonal and click chemistry: From molecular design to function.
8. 通过生物正交和点击化学设计响应性聚合物药物递送系统：从分子设计到功能PMID:日期:2026-09-03Stimuli-responsive polymer systems have been rapidly gaining attention for the targeted release of therapeutics. Such systems often require the construction of complex, multi-functional materials. Advancements in click and bioorthogonal reactions have therefore been increasingly used to prepare these polymeric materials, both through their synthesis in the lab as well as in their assembly in vivo at the target site. Furthermore, such reactions can even be used to trigger therapeutic release. This review will cover the main bioorthogonal and click reactions used for polymeric delivery systems including copper(I)-catalyzed azide-alkyne cycloaddition, strain-promoted cycloadditions, inverse electron demand Diels-Alder reactions, imine and hydrazone formation, and reactions of thiols such as thiol-ene, thiol-yne, thiol-Michael, and disulfide exchange. It will also provide an overview of the most important stimuli used to actuate drug release including changes in pH or redox status, enzymes, and external stimuli such as heat and light. The applications of this chemistry in a range of polymeric systems including polymer-drug conjugates, nanoparticles, polyion complexes, hydrogels, and nanogels will then be discussed. Finally a perspective of the current status of the field, challenges and areas for future exploration will be presented.
-
9. From conventional biologics-device combination products to advanced therapies: current state and future trends in patient-centric delivery.
PMID:日期:2026-09-01Patient-centric Biologics-Device Combination Products (BDCP) improve patient experience and compliance, while enhancing therapeutic outcomes by enabling novel routes of delivery, tackling frequent dosing and large-volume delivery requirements, and/or by simplifying administration in a healthcare setting as well as in out-patient dosing (e.g. self-administration). They also present promising solutions to overcome vaccine immunization challenges, particularly in developing nations. The BDCP opportunities, however, are often tempered by intrinsic properties of biologics (e.g. stability, viscosity etc.) and devices (e.g. design control, human factor engineering etc.) which can be further compounded by regulatory complexity across multiple jurisdictions. This comprehensive review examines the current landscape of combination product spanning across the complexities of modality (e.g. proteins, vaccines, oligonucleotide, mRNA/lipid nanoparticle (LNP) and to a limited extent cell & gene therapy) and delivery (parenteral, oral, ocular etc.) through the lens of business drivers, phase-appropriate technical development, regulatory frameworks, and patient-centric design principles. Selected case studies and commercially approved products for each modality are also presented here. Continued investments in new and improved devices such as prefilled syringes, wearable pumps, pen devices, jet devices and autoinjectors for liquid and lyophilized products highlight the recent paradigm shift for integration of delivery devices from self-administration to personalized medicine. Persistent innovation in the field, for example, has enabled device integration beyond chronic conditions such as diabetes and autoimmune diseases and prophylactic vaccination such as flu to cancer immunotherapy. Furthermore, technical, clinical and regulatory successes in achieving novel routes of delivery (e.g. oral biologics, inhaled insulin, inhaled vaccines, intradermal vaccination etc.), smart delivery systems and digital technologies have further advanced the boundaries of BDCP to not only increase market penetration but create new markets. This not only benefits patients worldwide but also paves the way for precision medicine in the future.
-
10. Engineering peptide-drug conjugates for targeted cancer therapy: design principle, theranostic imaging, and translational challenges.
10. 用于靶向癌症治疗的工程化肽-药物偶联物：设计原则、诊疗成像及转化挑战PMID:日期:2026-08-31Peptide-drug conjugates (PDCs) are emerging as a next-generation class of targeted therapeutics designed to overcome key limitations associated with conventional chemotherapy and antibody-drug conjugates (ADCs). By integrating a tumor-homing peptide, a cleavable or stimuli-responsive linker, and a potent cytotoxic payload, PDCs offer enhanced tumor selectivity while maintaining structural simplicity and synthetic flexibility. Compared to bulky monoclonal antibody-based systems, PDCs possess significantly smaller molecular size, enabling improved tumor penetration, rapid tissue diffusion, and reduced immunogenicity. Recent advances in peptide engineering have facilitated the development of ligands targeting integrins, G protein-coupled receptors, and other tumor-overexpressed biomarkers, promoting receptor-mediated internalization and intracellular drug release. Linker chemistry plays a pivotal role in therapeutic performance, with enzyme-sensitive, redox-responsive, and pH-cleavable linkers enabling site-specific drug activation within the tumor microenvironment. Despite their promise, PDCs face challenges including rapid renal clearance, proteolytic degradation, and limited circulation half-life. Strategies such as cyclization, PEGylation, and albumin-binding modification have been explored to enhance stability and pharmacokinetics. Furthermore, emerging theranostic PDC platforms incorporate imaging moieties or radiolabels, enabling real-time visualization of tumor targeting, biodistribution, and treatment response. Such dual-functional systems facilitate biomarker-guided patient stratification and image-guided precision therapy. This review comprehensively discusses the structural design principles, delivery barriers, pharmacokinetic considerations, applications, imaging advancements, and current clinical landscape of PDCs, highlighting their advantages over ADCs and outlining future directions for precision oncology. Collectively, PDCs represent a promising and versatile platform poised to redefine targeted cytotoxic delivery in cancer therapy.